In addition, MET and EGFR inhibitor combination has had some effect in patients with EGFR-mutant NSCLC that developed resistance to prior EGFR-targeted therapies through MET gene amplification (127). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.